🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Board Director Changes SEC Filings — May 20, 2026

This batch of 50 filings covering the period May 20, 2026, reveals a significant wave of C-suite and board-level transitions, with CEO changes at major firms like Wendy's and Choice Hotels, and CFO appointments at Philip Morris, Skillz, and Caleres. The data shows a clear trend of companies appointing internal successors or returning former executives, suggesting a preference for continuity. Forward-looking statements, including reaffirmed guidance at Choice Hotels and Turtle Beach, indicate that leadership changes are not expected to disrupt near-term financial performance. Insider activity is limited, but the extension of CEO Michael Mazzei's contract at BrightSpire Capital with reduced compensation targets presents a unique mixed signal. Overall, the market is absorbing a high volume of governance changes, which could create volatility but also opportunities for investors focused on strategic realignment.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 20, 2026

The three filings reveal a bifurcated M&A landscape: strategic bolt-on acquisitions in defense tech (Red Cat/Quaze) and manufacturing capacity expansion (XPEL) contrast with a purely procedural SPAC unit separation (QDRO). Red Cat's acquisition of Quaze Technologies addresses a critical operational bottleneck in drone autonomy—wireless recharging—with immediate cross-domain applicability, while XPEL's $110M investment in US and China manufacturing capacity signals confidence in long-term demand, backed by reaffirmed mid-20% operating margin targets for 2028. The QDRO filing offers no financial or operational content, serving only as a reminder of the SPAC market's ongoing technical adjustments. Across the two material filings, both companies are deploying capital for growth rather than shareholder returns, with no dividends or buybacks disclosed. Insider trading activity was absent from all three filings, limiting conviction signals. The key portfolio-level theme is capital deployment into tangible assets (IP, facilities) to capture vertical integration and operational efficiency gains.

3 high priority 3 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 20, 2026

Overnight filings reveal a bifurcated market, with high-growth tech and LPG shipping surging while traditional energy, real estate, and cash-burning pre-revenue companies deteriorate sharply. Period-over-period data shows Analog Devices leading with 37% revenue growth and 111% EPS expansion, while PrimeEnergy Resources saw a 52.5% net income decline. Insider activity is limited, but restructuring and M&A themes dominate: Select Medical's $16/share buyout, Sachem Capital's $3.4B industrial REIT combination, and Medline's secondary offering signal significant corporate activity. Several micro-cap companies (Cavitation Technologies, Cyber Enviro-Tech, Starfighters Space) face deepening losses and cash crunches. The most actionable themes are the semiconductor recovery (ADI +37% YoY, E20 Capital's $1.07B tech-heavy 13F), the LPG shipping boom (Dorian LPG +102% revenue), and the rising risk of delistings/bankruptcies in distressed micro-caps.

25 high priority 25 medium 50 total filings
· daily

NME Blockbuster Approvals — May 19, 2026

During the single-day period of May 19, 2026, the FDA issued one approval classified as 'Other' (FALLBACK type), with no NMEs, biosimilars, or label expansions recorded. The sole event was the NME approval of SONROTOCLAX (BEGALZI) from BEONE MEDICINES USA, granted Priority Review and Orphan Drug designations—a bullish signal for a rare disease asset. However, the lack of disclosed peak sales estimates, exclusivity terms, or pricing power limits the immediate commercial conviction. The dominant theme is a targeted rare disease NME launch, but the sparse approval volume offers no sector-wide therapeutic area clustering. Key watch items include the undisclosed market positioning and the absence of near-term catalysts beyond the approval itself.

1 total filings
· daily

Big Pharma Approvals — May 19, 2026

During this period, the FDA issued three label expansion approvals, all classified as 'FALLBACK' type, with zero NMEs, biosimilars, or standard label expansions. The dominant therapeutic area is immunology/inflammation, with Genentech Inc securing two approvals for its anti-PD-L1 franchise (TECENTRIQ HYBREZA and TECENTRIQ) and AstraZeneca AB obtaining one for its anti-IL-5Rα biologic FASENRA (benralizumab). The highest-conviction signal is the dual approval for Genentech's atezolizumab formulations, which strengthens its competitive position in oncology by offering both IV and subcutaneous delivery options. However, the lack of NME approvals and the 'FALLBACK' designation—which may indicate supplemental or minor label updates—limits the commercial upside and catalyst intensity. Key risk: without disclosed indication details or peak sales estimates, the materiality of these expansions remains uncertain, and investors should watch for payer coverage decisions and competitive dynamics in the PD-L1 and severe asthma markets.

3 total filings
· daily

Orphan Drug Approvals — May 19, 2026

This digest covers a single Orphan Drug Approval on May 19, 2026, with no NMEs, biosimilars, or label expansions recorded. The sole event is the FDA NME approval of SONROTOCLAX (BEGALZI) by BEONE MEDICINES USA, granted Priority Review and Orphan Drug designation, representing a high-conviction bullish signal for a novel therapy in a rare disease setting. The absence of other approvals limits therapeutic area clustering, but the single approval underscores BEONE MEDICINES USA's execution capability in bringing an NME to market with regulatory incentives. Key watch items include commercial launch dynamics and pricing strategy, as the drug’s peak sales and exclusivity details remain undisclosed, creating uncertainty around revenue potential.

1 total filings
· daily

New Drug Approvals (Original) — May 19, 2026

The May 19, 2026 FDA approval stream is dominated by biosimilar and generic approvals (11 of 12), with zero NMEs and one label expansion, signaling a period of market access expansion rather than novel drug innovation. The highest-conviction signal is the NME approval of SONROTOCLAX (BEGALZI) by BEONE MEDICINES USA, which received Priority Review and Orphan Drug designations, indicating a high-value, targeted therapy with strong regulatory endorsement. The biosimilar approval of GALLIUM GA-68 GOZOTETIDE by IONETIX via an unusual ANDA pathway introduces a lower-cost diagnostic alternative in the radiopharmaceutical space, bullish for the entrant but bearish for the undisclosed originator. The absence of NMEs and the high volume of biosimilar/generic approvals (10 of 12) suggest a market focus on cost containment and competitive erosion, with no new therapeutic area clusters emerging. Key watch items include the commercial launch of SONROTOCLAX and formulary access decisions for IONETIX’s diagnostic agent, as well as the IRA exposure of any small-molecule biosimilars approved this period.

12 total filings
· daily

New Federal Contractors — May 19, 2026

The sole contract recorded for May 19, 2026, is a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by the General Services Administration (GSA) FEDSIM for civil-military support services. This is a civilian agency award with no defense-related component, and the aggregate obligation of $116.2M carries a neutral signal strength of 5/10. The contract's negative outlay (-$287K) and minimal subawards suggest negligible revenue recognized to date, limiting near-term financial impact. Key risks include award fee variability under cost-plus pricing and execution uncertainty given the low outlay, while the fully competed nature confirms Booz Allen's competitive positioning in professional support services.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 19, 2026

The single contract analyzed for May 19, 2026, is a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM for civil-military support services, representing a purely civilian obligation with zero defense exposure. The contract's neutral signal strength (5/10) and low materiality (3/10) are driven by a negative outlay (-$287K) and minimal subawards ($100K), indicating negligible revenue recognized to date and limited near-term financial impact. The award confirms sustained demand for interagency professional support services, but the cost-plus-award-fee structure introduces margin uncertainty tied to performance metrics. Key watch items include monitoring future outlay amounts to validate revenue recognition and tracking potential modifications beyond the March 2024 end date.

1 total filings
· daily

Contract Deobligations Alert — May 19, 2026

This digest covers a single $116.2M contract deobligation alert for Booz Allen Hamilton from the General Services Administration (GSA) FEDSIM, representing a civilian-sector award with zero defense exposure. The contract, a cost-plus-award-fee delivery order for civil-military support services, shows a negative outlay (-$287K) and minimal subawards ($100K), indicating limited revenue recognition to date and a neutral near-term financial impact. The highest-conviction signal is the lack of material revenue contribution, while the key risk is the award-fee variability tied to performance metrics. Investors should monitor future outlay adjustments to gauge contract execution and potential revenue realization.

1 total filings
· daily

Contract Option Exercises — May 19, 2026

The single contract digest for May 19, 2026, features a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by the General Services Administration (GSA) FEDSIM for civil-military support services. This is a purely civilian award with no defense-related content, signaling stable demand for interagency professional support services but with a neutral investment signal due to a negative outlay (-$287K) indicating minimal revenue recognized to date. The contract's cost-plus pricing structure reduces downside risk but ties profit to performance metrics, creating margin uncertainty. The highest-conviction signal is the lack of near-term financial impact, as the negative outlay suggests deobligated funding or minimal work performed, making this a low-materiality event for investors. Key risk is the contract's March 2024 end date, which is already past, raising questions about extensions or modifications that are not reflected in the data.

1 total filings
· daily

Federal Professional Services Contracts — May 19, 2026

This single-contract digest covers a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM for civil-military support services, with zero defense-related contracts in the period. The contract is fully competed and not set aside, indicating Booz Allen won on merit, but the negative outlay (-$287K) and minimal subawards ($100K) suggest negligible revenue recognized to date, limiting near-term financial impact. The dominant theme is stable demand for professional support services in interagency coordination, though the cost-plus-award-fee structure introduces margin uncertainty. Key risk is the contract's March 2024 end date and potential for deobligation, while the neutral signal strength (5/10) and low materiality (3/10) reduce conviction for immediate investment action.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 19, 2026

The single contract in this period, a $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM, is a civilian-sector award (0/1 defense-related) for civil-military support services. The contract carries a neutral signal with a low materiality score of 3/10, primarily due to a negative outlay (-$287K) suggesting minimal revenue recognized to date and potential deobligation of funds. While the award confirms Booz Allen’s competitive standing in professional support services, the contract type introduces margin uncertainty tied to performance metrics. The key risk is the lack of near-term revenue visibility, as the negative outlay implies limited financial impact through the March 2024 end date. Investors should monitor future outlay data and any modifications to assess revenue recognition and contract execution.

1 total filings
· daily

General Federal Contracts — May 19, 2026

This digest covers a single $116.2M cost-plus-award-fee delivery order awarded to Booz Allen Hamilton by GSA FEDSIM for civil-military support services through March 2024. The contract is fully civilian (0% defense-related) and represents a neutral signal with medium materiality. While the award confirms Booz Allen’s competitive strength in interagency professional support services, the negative outlay (-$287K) and minimal subawards ($100K) indicate negligible revenue recognition to date, limiting near-term financial impact. Key risks include award fee variability under cost-plus pricing and potential deobligation, while the primary watch item is future outlay data to confirm revenue ramp.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 19, 2026

The 12 filings reveal a bifurcated S&P 500 Technology landscape: established hardware leaders like Cisco are delivering strong revenue growth (12% YoY) and margin expansion, while smaller, speculative tech and biotech names show mixed signals—ranging from a major equity turnaround at AIM ImmunoTech to a widening loss at Bravo Multinational. A clear thematic driver is the AI infrastructure buildout, evidenced by Blockchain Digital Infrastructure's tripling operating cash flow and Analog Devices' strategic acquisition of Empower Semiconductor. Insider activity is sparse but notable for the lack of selling, while capital allocation trends point to reinvestment (M&A) over shareholder returns. Forward-looking catalysts are concentrated in biotech (Immunic's Phase 3 readout) and AI data center development (Blockchain Digital's 395 MW pipeline). The most actionable insights center on Cisco's operational efficiency, Immunic's upcoming trial catalyst, and the sector-wide push into power management and AI compute capacity.

4 high priority 8 medium 12 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 19, 2026

The May 19, 2026 filing batch for the NASDAQ-100 stream reveals a bifurcated market with strong operational performance at scale (Cisco) contrasting with micro-cap distress (Bravo Multinational, AIM ImmunoTech). The dominant theme is strategic portfolio repositioning: Cisco delivered a standout 12% YoY revenue beat with 35% net income growth, while Analog Devices and Maui Land & Pineapple are pursuing transformative M&A/asset sales. The XAI Madison Equity Premium Income Fund is executing a strategic sub-adviser addition to diversify its income strategy, signaling a shift toward preferred equity. However, the small-cap names show acute financial strain—Bravo Multinational's net loss widened 82% YoY, and AIM ImmunoTech only recently climbed out of a negative equity position. Insider activity is notably absent across the large-cap filers, while capital allocation actions (Kennametal's debt tender, PayPal's equity plan) suggest a focus on balance sheet management. The forward-looking catalyst calendar is anchored by Immunic's Phase 3 MS trial readout (YE 2026) and ADI's Empower Semiconductor deal closing (H2 2026), offering event-driven opportunities. Overall, the data signals a 'flight to quality' within the NASDAQ-100, where scale, cash flow, and strategic clarity are rewarded, while smaller names face existential refinancing risks.

5 high priority 7 medium 12 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 19, 2026

The 50 filings for the S&P 500 Financials sector on May 19, 2026, reveal a sector bifurcated between strong revenue growth and significant margin compression. While top-line growth is evident across several sub-sectors (e.g., Energy Vault's 156% YoY revenue surge, Eagle Materials' record $2.3B revenue), profitability is under severe pressure, with net earnings declining at major firms like Home Depot (-4.2% YoY) and Eagle Materials (-9% YoY). The most critical developments include a wave of SPAC activity and business combinations (Plum Acquisition, SoftVest, Bleichroeder), signaling a potential consolidation phase, alongside notable insider actions like GitLab's chair converting all super-voting shares, which reduces governance risk. Capital allocation trends show a mix of aggressive buybacks (News Corp's $1B program) and strategic debt financing (Granite Construction's $600M notes), indicating a focus on shareholder returns and growth investment. A key portfolio-level pattern is the 'growth at all costs' theme, where companies like Thermon Group and Energy Vault are sacrificing near-term GAAP profitability for long-term market share and strategic positioning, a trend that demands careful scrutiny of cash burn rates and debt levels.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 19, 2026

The 50 filings from the S&P 500 Consumer Staples sector reveal a sector under significant pressure, with mixed results across the board. While top-line growth is evident in some areas (Novelis +7.5% YoY, Thermon +11% YoY), profitability is being squeezed by rising costs, operational disruptions, and strategic investments. A key theme is the divergence between operational metrics and financial results, as seen in Under Armour's widening net loss (-$495.6M) despite cost-cutting, and Educational Development Corp's profit turnaround driven by a one-time asset sale. Insider activity is limited, but capital allocation is active, with major debt offerings (Pinnacle Financial $750M, Blackstone Mortgage $450M) and a significant share repurchase (HF Sinclair $100M). The most critical developments include the pending $2.2B Thermon/CECO merger, Paramount Skysdance's $51.9B acquisition financing plan for Warner Bros. Discovery, and Novelis's operational recovery from the Oswego plant fires. Portfolio-level patterns point to a sector grappling with inflation, supply chain issues, and the need for strategic transformation, creating a landscape of both significant risks and selective opportunities for investors.

18 high priority 32 medium 50 total filings